Let me refer you to the biz model once again - holding company. Lympro will be sold. Eltoprazine will be sold. ESS will be sold. Any other under valued asset will be bought then sold. You should be more concerned about how much money AMBS will get from Lympro than the 2015 and 2016 revenue numbers. All of this is to eventually develop a biotech company with MANF.